Laboratory Testing for Pituitary Disorders and Brain Tumors
All patients with suspected pituitary pathology should undergo comprehensive hormonal evaluation including prolactin, IGF-1, morning cortisol with ACTH, TSH with free T4, and assessment of gonadal function, as these tests detect both hormone hypersecretion and deficiency that may not be clinically apparent 1, 2.
Core Laboratory Panel
Mandatory Initial Tests
For hormone hypersecretion screening:
- Prolactin - Essential in all patients, as hyperprolactinemia occurs in 8.8-24% of incidentally discovered pituitary lesions 3. For large tumors (>1cm), request diluted serum measurement to avoid falsely low results from the "hook effect" 2
- IGF-1 (age and sex-matched) - Screens for growth hormone excess, which may be clinically silent. Up to 45.9% of apparently non-functioning adenomas show GH immunostaining 1
- Morning cortisol with ACTH - Identifies both Cushing's disease and secondary adrenal insufficiency 4, 5
- TSH with free T4 - Detects both TSH-secreting tumors and central hypothyroidism 1, 2
For hypopituitarism assessment:
- LH, FSH with testosterone (males) or estradiol (premenopausal females) - Central hypogonadism occurs in 36-96% of pituitary adenomas 1
- Electrolytes - Hypernatremia suggests diabetes insipidus, though this is rare (<7%) unless apoplexy has occurred 1
Dynamic Testing When Baseline Results Are Equivocal
Growth hormone axis:
- Oral glucose tolerance test (75g glucose with GH measurements every 30 minutes for 2 hours) - Normal GH nadir should be <0.4 ng/mL with current sensitive assays, though <1 ng/mL remains the traditional cutoff 6
Adrenal axis:
- ACTH stimulation test when morning cortisol is 3-15 μg/dL 4
- Consider cosyntropin stimulation if secondary adrenal insufficiency is suspected 7
Cushing's disease screening (only if clinical features present):
- Late-night salivary cortisol is the best initial screening test 8
- Overnight 1mg dexamethasone suppression test 9
Critical Pitfalls to Avoid
Distinguishing primary from secondary endocrine dysfunction:
- Low ACTH with low cortisol indicates central (pituitary/hypothalamic) adrenal insufficiency, not primary adrenal disease 4, 5
- In central hypothyroidism, TSH may be low, normal, or even slightly elevated - free T4 is the key parameter, not TSH 4, 5
Hyperprolactinemia interpretation:
- Prolactin >150-200 ng/mL (or >2000 mU/L) virtually always indicates prolactinoma 2, 8
- Mild elevations (typically <100 ng/mL) may represent "stalk effect" from any mass compressing the pituitary stalk, not a prolactinoma 3, 8
Timing considerations:
- Never start thyroid hormone replacement before confirming adequate cortisol - this can precipitate life-threatening adrenal crisis 4, 5
- Patients on corticosteroids for other conditions will have suppressed morning cortisol and ACTH - diagnosis of adrenal insufficiency cannot be made until steroids are discontinued 5
Prevalence of Abnormalities
Understanding pretest probability guides interpretation:
- Overall hypopituitarism: 37-85% of non-functioning pituitary adenomas 1
- GH deficiency: Most common, affecting 61-100% 1
- Central hypogonadism: 36-96% 1
- Adrenal insufficiency: 17-62% 1
- Central hypothyroidism: 8-81% 1
- Panhypopituitarism: 6-29% 1
Additional Considerations for Specific Scenarios
When multiple pituitary deficiencies are present:
- Strongly consider MRI brain with dedicated pituitary protocol (with and without contrast) to evaluate for mass effect, even if tumor was not initially suspected 6, 4
- Visual field testing is mandatory if optic chiasm compression is noted or if peripheral vision complaints exist 6
Genetic predisposition screening:
- Family history of multiple endocrine neoplasia, young age at presentation, or multiple family members with cancer warrant consideration of genetic syndromes 10
Laboratory monitoring during immunotherapy:
- Patients receiving checkpoint inhibitors (ipilimumab, etc.) require routine TSH, free T4, ACTH, and morning cortisol monitoring before each infusion, as hypophysitis is a recognized complication 4, 7
The evidence strongly supports comprehensive anterior pituitary axis evaluation in all patients rather than selective testing based on clinical suspicion alone, as hormone abnormalities frequently occur without obvious clinical manifestations 1, 2.